menu
    • menu
    [{"orgOrder":0,"company":"Catalysis - S.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Carminal","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Catalysis - S.L.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Catalysis - S.L. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis - S.L. \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis - S.L.","sponsor":"Catalysis - S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GREECE","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Ocoxin","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalysis - S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Catalysis - S.L. \/ Catalysis - S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Catalysis - S.L. \/ Catalysis - S.L."}]

    Find Clinical Drug Pipeline Developments & Deals by Catalysis - S.L.

    Menu

    Catalysis - S.L.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Catalysis - S.L.

                            Spain arrow
                            IPEX Indonesia
                            Not Confirmed

                            Catalysis - S.L.

                            Spain arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ocoxin

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Aristotle University Of Thessaloniki

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study

                            Details : Ocoxin is a Dietary Supplement drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            October 07, 2025

                            Lead Product(s) : Ocoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Aristotle University Of Thessaloniki

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Catalysis - S.L.

                            Spain arrow
                            IPEX Indonesia
                            Not Confirmed

                            Catalysis - S.L.

                            Spain arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carminal

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Carminal in Helicobacter Pylori Gastritis

                            Details : Carminal is a Dietary Supplement drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Helicobacter Pylori Gastritis.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            September 17, 2025

                            Lead Product(s) : Carminal

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth